Lemaitre Vascular Inc. logo

Lemaitre Vascular Inc. (LHU)

Market Open
15 Oct, 06:04 AM
XMUN XMUN
€
73. 50
0
0%
€
1.86B Market Cap
46.73 P/E Ratio
0.64% Div Yield
370 Volume
1.65 Eps
€ 73.5
Previous Close
Add Transaction
Day Range
73.5 73.5
Year Range
68 101
Want to track LHU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LHU trading today higher at €73.5, an increase of 0% from yesterday's close, completing a monthly increase of 1.3793% or €1. Over the past 12 months, LHU stock gained 5.7554%.
LHU pays dividends to its shareholders, with the most recent payment made on Sep 03, 2026. The next estimated payment will be in In 1 month on Dec 03, 2026 for a total of €0.25.
The last earnings report, released on May 07, 2026, missed the consensus estimates by -0.66%. On average, the company has fell short of earnings expectations by -0.1531%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

LHU Chart

People also search for

Toshiba Tec Corp.
€ 16.9
0%
9QQ
Asseco Business Solutions S.A.
€ 19.4
+0.2584%
Chinasoft International Limited
€ 0.41
0%
TBY
Business Engineering Corporation
€ 7.7
+0.6536%
1VW
Cerillion plc
€ 8.1
0%
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine

LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine

LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.

Seekingalpha | 2 weeks ago
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut

LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut

LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.

Seekingalpha | 2 months ago
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

Lemaitre Vascular Inc. (LHU) FAQ

What is the stock price today?

The current price is €73.50.

On which exchange is it traded?

Lemaitre Vascular Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is LHU.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.64%.

What is its market cap?

As of today, the market cap is 1.86B.

Has Lemaitre Vascular Inc. ever had a stock split?

No, there has never been a stock split.

Lemaitre Vascular Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
George W. LeMaitre CEO
XMUN Exchange
US5255582018 ISIN
US Country
651 Employees
20 Aug 2026 Last Dividend
- Last Split
19 Oct 2006 IPO Date

Overview

LeMaitre Vascular, Inc. is a global company focused on the design, manufacture, and marketing of medical devices and implants for vascular surgery. Initially founded as Vascutech, Inc., the company transitioned to its current name in April 2001. With its beginnings in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular stands as a pioneer in the vascular health sector. It offers a diverse range of products, including devices for blood vessel viewing, blood clot removal, and vascular reconstruction, catering to the needs of surgeons and patients worldwide. The company’s approach combines innovative technology with practical applications in vascular surgery, distributing its products through a direct sales force and a network of distributors.

Products and Services

  • Human Cadaver Tissue Cryopreservation Services: Provides preservation services for human cadaver tissues, making them available for various medical uses.
  • Angioscope: A fiberoptic catheter for viewing the inside of blood vessels, aiding in diagnostics and surgery planning.
  • Embolectomy Catheters: Designed for the removal of blood clots from arteries to restore normal blood flow and prevent tissue damage.
  • Thrombectomy Catheters: Specialized catheters for removing thrombi in the venous system, essential in treating venous thromboembolism.
  • Occlusion Catheters: Temporarily occlude blood flow to facilitate various surgical procedures without significant blood loss.
  • Perfusion Catheters: Allow for the delivery of blood and other fluids into the vasculature, crucial for maintaining tissue viability during surgery.
  • Artegraft Biologic Graft: A bovine carotid artery graft used primarily for dialysis access, offering a durable alternative to synthetic grafts.
  • XenoSure Biologic Patches: Used for vessel closure after surgical interventions, promoting natural healing and vessel function restoration.
  • VascuCel and CardioCel Biologic Patches: Biologic patches for vessel, heart, and neonatal repairs, made to integrate seamlessly with the body’s tissues.
  • Carotid Shunts: Temporarily divert blood to the brain during carotid endarterectomy procedures, ensuring cerebral protection.
  • Biosynthetic Vascular Graft: Indicated for lower extremity bypass and dialysis access, combining the benefits of synthetic and biologic graft materials.
  • Vascular Grafts: Used to bypass or replace diseased arteries, these grafts are critical in restoring normal blood flow to affected limbs.
  • Radiopaque Tape: A medical-grade tape that helps surgeons and interventionalists locate vascular tributaries or lesions beneath the skin.
  • Valvulotomes: Instruments for modifying the saphenous vein to function as an artificial artery, a vital step in some bypass procedures.
  • Closure Systems: Provide an alternative to sutures for attaching vessels, utilizing titanium clips for a secure, leak-proof connection.

Contact Information

Address: 63 Second Avenue
Phone: 781 221 2266